Summary of Invention
Genetic profiling of tumors is an effective approach to cancer treatment. There is an unmet need in this field to better understand the genetic profile of different classes of tumors in an effort to tailor the therapy to suit individual needs.
The present invention provides identification of a gene expression profile that predicts the anticancer activity of inhibitors of the RAF/MEK/MAPK pathway. This technology could be used for qualifying the cancer status and response in patients, for monitoring the efficacy of a chemotherapeutic regimen and for screening new compounds
Advantages
- Excellent prognostic indicator in improving patient outcomes
- Sensitive detection of anti-tumor response
- Potential to tailor individual treatment regimen
- Screening tool for new compounds
- Novel therapeutic targets
Areas of Application
Therapeutic, prognostic, and research tool
Stage of Development
In-vitro cell line and xenograft studies
Lead Inventors
- Dr. Christine Pratilas
- Dr. Neal Rosen
Patent Information
Patent protection available in the US (Pub No: US-2008-0131885-A1)
References
Contact Information:
Imke Ehlers, PhD
Tel: 212-639-6181; Fax: 212-717-3439
E-mail: ehlersi@mskcc.org
